Cluenex
Log inStart free
All stocks · Healthcare · Biotechnology

Amgen Inc AMGN

Amgen Inc scores good on business quality (6.4 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$414.87Oct 9, 2026
Business qualityGood
Next earningsNov 3, 2026, after the close
Insiders, 90 daysSelling

Why it matters

  1. What Amgen Inc does

    Amgen discovers and manufactures human therapeutics for serious illnesses, selling primarily to healthcare providers and institutions globally.

  2. What it does best

    Amgen dominates complex biologic drug manufacturing, delivering a gross margin of 74% that edges out AbbVie's 72.8%. This scale creates high barriers to entry since replicating these facilities requires years of capital outlay.

  3. The main risk

    A heavy debt load of $54.6 billion combined with an interest coverage ratio of 5.1x leaves little room for operational missteps as borrowing costs pressure the bottom line.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityStrong

Operating margins sit at 35.9% with an exceptional return on equity of 89.3%, showing that the business generates strong returns on capital as it scales.

MoatStrong

Complex manufacturing expertise and patented biologic processes secure its enterprise customer base, placing operating margins in the top decile of its sector at 92%.

GrowthSteady

Revenue grew 9.9% to $38.1 billion, accelerating from prior years as newer biologic treatments expand market share.

Financial healthWeak

With total debt at $54.6 billion against $9.1 billion in cash, leverage is high with a debt-to-equity ratio of 6.3x, leaving the balance sheet soft.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

3 sold $4.1M outside pre-planned sales.

Our sealed record on AMGN

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is AMGN a good business?

Amgen Inc scores good on the Cluenex quality check (6.4 of 10), measured against its own industry. Profitability is strong, moat strong, growth steady and financial health weak.

Are insiders buying AMGN?

In the last 90 days of SEC Form 4 filings: 3 sold $4.1M outside pre-planned sales.

When does AMGN report earnings?

Nov 3, 2026, after the close.

For members

See AMGN today

  • Today's verdict on AMGN, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Amgen Inc (AMGN)”, https://cluenex.com/stocks/amgn/, data as of Oct 10, 2026.